Helping patients get groceries and make meals while staying on a DASH-approved diet not only helped, but people liked it, too ...

The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

The results, which are mostly relevant to an older population, address a common dilemma for aortic stenosis patients with CAD ...

The first RCT to compare valve-in-valve vs redo surgery reassures, especially for regions where rheumatic valve disease is prevalent.

(CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated ...

Mamas Mamas speaks with John Davies and J. Dawn Abbott about outcomes when treating patients with chronic total occlusions with PCI.

The trial enrolled just half of its planned patients, leaving spironolactone’s role in HFpEF and HFmrEF still up in the air.

In carefully selected patients with CTOs, symptom-driven PCI does provide a benefit when done by experienced operators.

While the noninvasive methods used different technologies to calculate flow, both were noninferior to the gold standard.

The results challenge the rapid growth of Impella support during high-risk PCI. Investigators say a reckoning is needed.